Ionis Pharmaceuticals Inc (NASDAQ:IONS) – William Blair issued their FY2019 EPS estimates for shares of Ionis Pharmaceuticals in a research note issued on Thursday, November 14th. William Blair analyst M. Minter expects that the company will earn $0.61 per share for the year. William Blair has a “Market Perform” rating on the stock. William Blair also issued estimates for Ionis Pharmaceuticals’ Q4 2019 earnings at $1.24 EPS, FY2020 earnings at $1.09 EPS, FY2021 earnings at $1.38 EPS and FY2022 earnings at $2.06 EPS.
Other analysts also recently issued reports about the company. Needham & Company LLC reiterated a “buy” rating and set a $87.00 target price on shares of Ionis Pharmaceuticals in a research note on Thursday, November 7th. Morgan Stanley downgraded Ionis Pharmaceuticals from an “equal” rating to a “weight” rating and dropped their price target for the stock from $63.00 to $48.00 in a research note on Thursday, November 7th. Piper Jaffray Companies dropped their price target on Ionis Pharmaceuticals from $75.00 to $70.00 and set a “neutral” rating on the stock in a research note on Thursday, November 7th. Wells Fargo & Co raised their price target on Ionis Pharmaceuticals from $90.00 to $120.00 and gave the stock an “outperform” rating in a research note on Thursday, October 10th. Finally, BidaskClub upgraded Ionis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the company. Ionis Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $73.67.
Shares of IONS opened at $58.09 on Monday. The business’s fifty day simple moving average is $57.40 and its two-hundred day simple moving average is $63.51. The company has a current ratio of 10.39, a quick ratio of 10.31 and a debt-to-equity ratio of 0.44. Ionis Pharmaceuticals has a 12 month low of $48.27 and a 12 month high of $86.58. The company has a market cap of $8.24 billion, a price-to-earnings ratio of 19.63, a P/E/G ratio of 2.27 and a beta of 1.90.
Ionis Pharmaceuticals (NASDAQ:IONS) last issued its earnings results on Wednesday, November 6th. The company reported $0.18 EPS for the quarter, beating the consensus estimate of ($0.31) by $0.49. Ionis Pharmaceuticals had a return on equity of 36.31% and a net margin of 52.26%. The business had revenue of $168.00 million for the quarter, compared to the consensus estimate of $152.47 million. During the same period last year, the business posted ($0.03) EPS. The company’s revenue was up 15.9% compared to the same quarter last year.
Hedge funds have recently added to or reduced their stakes in the company. Whittier Trust Co. boosted its stake in shares of Ionis Pharmaceuticals by 283.0% in the 2nd quarter. Whittier Trust Co. now owns 383 shares of the company’s stock worth $25,000 after buying an additional 283 shares during the last quarter. CWM LLC raised its holdings in Ionis Pharmaceuticals by 361.4% in the 2nd quarter. CWM LLC now owns 406 shares of the company’s stock worth $26,000 after purchasing an additional 318 shares during the period. Ellis Investment Partners LLC bought a new position in Ionis Pharmaceuticals in the 2nd quarter worth $32,000. Rehmann Capital Advisory Group raised its holdings in Ionis Pharmaceuticals by 41.3% in the 2nd quarter. Rehmann Capital Advisory Group now owns 592 shares of the company’s stock worth $38,000 after purchasing an additional 173 shares during the period. Finally, Quest Capital Management Inc. ADV bought a new position in Ionis Pharmaceuticals in the 3rd quarter worth $36,000. Hedge funds and other institutional investors own 87.27% of the company’s stock.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.